LEADERSHIP TEAM
OxThera is built on a highly-experienced and committed team and strong network in oxaluria research, rare disease drug development and anaerobic bacterial manufacturing.
Leadership Team and Strategic Advisor
LEADERSHIP TEAM
OxThera is built on a highly-experienced and committed team and strong network in oxaluria research, rare disease drug development and anaerobic bacterial manufacturing.
Leadership Team and Strategic Advisor
Matthew Gantz, Chief Executive Officer
Born 1965. CEO since 2017.
Education: BA from Princeton University. MBA from Harvard
University.
Other current assignments: Member of the board of
directors of Swedish Orphan Biovitrum AB and Marine Corps
Scholarship Foundation.
Previous assignments (last five years): EVP (US) at BTG plc.
Member of the board of directors of Life Sciences PA.
Shareholding in the Company: Matthew Gantz holds 10,618,294
Class A Options in the Company.
Mats-Olof Wallin, Chief Financial Officer
Born 1951. Deputy CEO since 2020 and CFO since 2020.
Education: BSc, Uppsala University
Other current assignments: Deputy board member and CEO
of OxThera Intellectual Property AB. Chairman of the board of
directors and CEO of Mowin Konsult AB.
Previous assignments (last five years): CFO of Karo Pharma AB
and Sobi AB.
Shareholding in the Company: Mats-Olof Wallin holds no
shares in the Company.
Bastian Dehmel, Chief Medical Officer
Born 1970. CMO since 2017.
Education: Staatsexamen from Freie Universitaet Berlin.
Doctoral Degree from the Humboldt University, Charite.
Other current assignments: -
Previous assignments (last five years): -
Shareholding in the Company: Bastian Dehmel holds 3,981,860
Class A Options in the Company.
Elisabeth Lindner, Strategic Advisor
Elisabeth Lindner is a Member of the Royal Swedish Academy of Engineering Sciences and has long-term senior management experience from Pharmacia Corporation, Octapharma, and Diamyd Medical among others. Mrs Lindner holds a MSc from the Royal Institute of Technology and an MBA from Uppsala University.